XML 48 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 23 - Fair Value Disclosures
12 Months Ended
Dec. 31, 2017
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
NOTE
23
– FAIR VALUE DISCLOSURES
 
Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.
 
The fair value of the Company’s financial instruments are as follows:
 
           
Fair Value Measured at Reporting Date Using
         
   
Carrying Amount
   
Level 1
   
Level 2
   
Level 3
   
Fair Value
 
At December 31, 2017:
                                       
Cash and cash equivalents
  $
84,978
    $
-
    $
84,978
    $
-
    $
84,978
 
Other receivables
  $
222,562
    $
-
    $
-
    $
222,562
    $
222,562
 
Note receivable - related party
  $
44,859
    $
-
    $
-
    $
44,859
    $
44,859
 
Advances to CEN Biotech
                                       
Ukraine, LLC - related party
  $
775,328
    $
-
    $
-
    $
775,328
    $
775,328
 
Loans payable
  $
9,981,883
    $
-
    $
-
    $
9,981,883
    $
9,981,883
 
Loans payable – related parties
  $
1,138,923
    $
-
    $
-
    $
-
    $
-
 
Convertible notes payable
  $
3,670,172
    $
-
    $
-
    $
3,831,760
    $
3,831,760
 
Convertible notes payable - related parties
  $
2,710,313
    $
-
    $
-
    $
-
    $
-
 
                                         
At December 31, 2016:
                                       
Cash and cash equivalents
  $
62,381
    $
-
    $
62,381
    $
-
    $
62,381
 
Advances to CEN Biotech
                                       
Ukraine, LLC - related party
  $
425,328
    $
-
    $
-
    $
425,328
    $
425,328
 
Loans payable
  $
9,962,287
    $
-
    $
-
    $
9,962,287
    $
9,962,287
 
Loans payable – related parties
  $
846,448
    $
-
    $
-
    $
-
    $
-
 
Convertible notes payable
  $
569,412
    $
-
    $
-
    $
587,184
    $
587,184
 
Convertible notes payable - related parties
  $
2,210,313
    $
-
    $
-
    $
-
    $
-
 
 
The fair values of the other receivables, note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.
 
The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.
 
The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.
 
It is
not
practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.